BNET Industries
Isis Pharmaceuticals Inc. (ISIS) is in the Pharma Industry
Latest News and Analysis
Isis Pharmaceuticals' Obesity Buster an Enormous Finding
Steven Turner submits: Logic may dictate that Isis Pharmaceuticals' largest multibillion-dollar blockbuster drug is its anti-lipid drug Mipomersen. After all, Genzyme GENZ has already paid Isis 325 million dollars upfront, and is scheduled to pay an additional 1.575 billion dollars in milestone payments. True, Mipomersen has...
In Tech We Trust - Fast Money Recap (6/20/08)
Recap of Fast Money, Friday June 20. Dow Falls Below 12,000 by SA Editor Joan Wickham
FDA Stings Pharma, Big and Small
Michael Steinberg submits: The first shock came after Merck MRK and Schering-Plough’s SGP Vytorin ENHANCE study. Surrogate markers like cholesterol counts would no longer be enough to garner marketing approval. Genzyme GENZ and Isis ISIS received the first blow. Isis’ cholesterol drug Mipomersen would have to undergo an outcomes study...
Investing in miRNA: Beware the Hype, Follow the Money
Ohad Hammer submits: The momentum in the microRNA miRNA field is continuing to build, as evidence that links this group of important genes to multiple diseases, from Alzheimer to diabetes, is constantly mounting. The adoption of miRNAs is further accelerated by the technological advancements in RNA-based therapies. Because miRNAs are...
Isis Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript
Isis Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript
ISIS Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript
ISIS Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript
ISIS Pharmaceuticals Q3 2007 Earnings Call Transcript
ISIS Pharmaceuticals Q3 2007 Earnings Call Transcript
Additional Resources
OncoGenex increases economic interest in lead cancer drug OGX-011
VANCOUVER, July 3 /PRNewswire/ -- OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. announced today that the companies have amended their agreement and OncoGenex has elected to independently develop its lead cancer drug OGX-011. Under the amended agreement, OncoGenex is solely responsible for all future development activities, costs and...
Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call
CARLSBAD, Calif., July 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announces the following webcast: What: Isis Pharmaceuticals' business update When: Tuesday, July 1, 2008, at 10:00...
Abbott Invests Additional $20M in Isis' Subsidiary Ibis Biosciences
CARLSBAD, Calif., July 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today that Abbott has invested an additional $20 million in Ibis Biosciences, Inc., an Isis subsidiary. The investment will allow Ibis to further develop the Ibis T5000TM Biosensor System, which offers a unique solution for rapid identification...
Isis Pharmaceuticals Conference Call Notice
-- Tuesday, July 1, 2008 -- 10:00 a.m. EDT, 7:00 a.m. PDT -- 877-548-7901 -- http://www.isispharm.com SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals will conduct a conference call at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, July 1,...
Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies
CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA miRNA therapeutics, announced today that it has been named to the annual FierceBiotech "Fierce 15" list, designating it as...
Genzyme and Isis Complete Licensing of Mipomersen
Conference call to be held today at 10 a.m. EDT CAMBRIDGE, Mass., and CARLSBAD, Calif., June 24 /PRNewswire-FirstCall/ -- Genzyme Corp. and Isis Pharmaceuticals, Inc. today announced the finalization of the license and collaboration agreement for mipomersen. The collaboration provides Genzyme with exclusive worldwide...
Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
- Oral presentation on the potent blood glucose lowering effect of SGLT2 antisense inhibitors in multiple preclinical models - Eight additional presentations highlight significant activity in eight new metabolic disease targets utilizing antisense SAN FRANCISCO and CARLSBAD, Calif., June 10 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc....
Webcast Alert: Isis Pharmaceuticals to Provide General Corporate Update in Conjunction With 2008 Annual Meeting of Stockholders
CARLSBAD, Calif., June 3 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announces the following webcast: What: Isis Pharmaceuticals to provide a general corporate update in conjunction with the 2008 Annual Meeting of Stockholders....
Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology
CHICAGO and CARLSBAD, Calif., June 2 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today that two of the Company's partnered oncology drugs were highlighted during the American Society of Clinical Oncology ASCO meeting. Data from both drugs highlighted positive activity that supports the continuation of clinical development, and...
FDA PROVIDES CLARITY TO ISIS ON MIPOMERSEN REQUIREMENTS.
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS)and Genzyme Corp. (NASDAQ:GENZ) has announced that the FDA has provided guidance regarding approval requirements for mipomersen. The FDA has indicated that reduction of LDL-cholesterol is an acceptable surrogate endpoint for accelerated approval of mipomersen for use in patients with homozygous familial...
Isis to Receive $4.6 Million From Alnylam
CARLSBAD, Calif., May 27 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today that it will receive $4.6 million dollars from Alnylam Pharmaceuticals, Inc. as its portion of the upfront fees in the recently announced transaction between Takeda Pharmaceutical Company Limited and Alnylam. In addition, Isis has the...
Isis Files S-3 Registration Statement
CARLSBAD, Calif., May 21 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today that it has filed a registration statement on Form S-3 with the Securities and Exchange Commission relating to the registration of five million shares of Isis common stock that was purchased on February 4, 2008 by Genzyme...
Isis Reports Financial Results and Highlights for First Quarter of 2008
- Conference Call Webcast Monday, May 12, 08:30 a.m. EDT at www.isispharm.com CARLSBAD, Calif., May 12 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended March 31, 2008. The Company finished the quarter with a pro forma net operating loss...
- Next »
- page 1 of 21
- « Previous
Sort byClose
- Incorporated: 1989
- CEO: Dr. Stanley T. Crooke M.D., Ph
Isis Pharmaceuticals develops human therapeutic drugs using antisense technology. As of Dec 31 2007, Co. had two principal segments: Drug Discovery and Development, which is using a drug discovery platform to create a pipeline of drugs for its drug pipeline and its partners' drug pipelines designed to treat a variety of health conditions, including cardiovascular, metabolic, inflammatory, ocular and neurodegenerative diseases, and cancer with 18 drugs in development; and Ibis Biosciences, Inc., a majority-owned subsidiary, which developed and is commercializing its biosensor technology, including the Ibis T5000 Biosensor System and assay kits.
Key Competitors
Isis Pharmaceuticals Inc. Company Info
Board of Directors
Dr. Stanley T. Crooke M.D., Ph
Chairman
Dr. Spencer R. Berthelsen
Ms. B. Lynne Parshall
Mr. Joseph H. Wender
Dr. Richard D. Dimarchi Ph.D.
Mr. Frederick T. Muto
Mr. Joseph Klein III
Dr. John C. Reed Ph.D.
Contact Information
1896 Rutherford Road
Carlsbad, CA
760 931-9200
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412Brought to you by IBMSponsored Resources
